<DOC>
	<DOCNO>NCT01344954</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy two dose TB-402 administered single intravenous infusion prevention VTE subject undergoing total hip replacement surgery .</brief_summary>
	<brief_title>Single IV Administration TB-402 Prophylaxis Venous Thromboembolic Events ( VTE ) After Total Hip Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>1 . Male female subject age â‰¥ 18 year . 2 . Written informed consent . 3 . Willing able comply schedule visit , treatment plan , laboratory test study procedure 1 . Pregnancy time screen . 2 . Indication anticoagulation postoperative thromboprophylaxis . 3 . Active bleeding high risk bleeding . 4 . Anticipated continue use neuraxial catheter surgery . 5 . Clinical laboratory finding screen thrombocytopenia prolong aPTT PT . 6 . Uncontrolled hypertension . 7 . Impaired liver function ( transaminase &gt; 3 X ULN ) history hepatic insufficiency . 8 . Creatinine clearance &lt; 30 mL/min . 9 . Antiplatelet agent low dose aspirin ( &lt; 200mg ) . 10 . The use intermittent pneumatic compression . 11 . Known hypersensitivity contrast medium rivaroxaban . 12 . Known drug alcohol abuse . 13 . Active malignant disease current cytostatic treatment . 14 . Stroke within previous month . 15 . Participation investigational drug study within past 30 day previous participation study . 16 . Any condition opinion investigator would put subject increase risk participate study expect inability comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>